The reason for this is its central role in melanoma, which is reflected in its frequent deregulation through mutations (CancerGenomeAtlasNetwork 2015), and these are found even more frequently in BRAF/MEK inhibitor resistant tumors (Shi et al., 2014; Van Allen et al., 2014). This evidence concerns the gene BRAF and melanoma.